ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX “Radiopharm”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the signing of a supply agreement that will provide Radiopharm with ITM’s medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. ¹⁷⁷Lu), to enable its usage in the clinical and potential future commercial development of the ¹⁷⁷Lu-based molecules in Radiopharm’s development pipeline.

Read more at globenewswire.com